NY-IFF
2.6.2022 22:17:09 CEST | Business Wire | Press release
IFF (NYSE:IFF) has released its 2021 environmental, social and governance plus sustainable solutions (or ESG+) performance report. Published today, “Transforming Our World ,” details the Company’s commitment to do more good for people and the planet, aligned with IFF’s purpose—Applying science and creativity for a better world. Centered around the recently launched Do More Good Plan , the report updates progress on legacy IFF targets, looks ahead to even more ambitious 2030 objectives, and aims to address the world’s most pressing sustainable development challenges from IFF’s perspective.
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET.
“At IFF, we’re taking a holistic approach to creating a better world by leveraging our business, performance and partners,” said Frank Clyburn, IFF CEO. “Since the launch of our first sustainability program in 2010, we’ve made tremendous progress. To continue driving results, we’re challenging our teams to be accountable, to collaborate across divisions, and to execute on our ESG+ strategy.”
“At today’s IFF, we’re taking another bold step, embedding a more comprehensive ESG structure in every part of our business, including the solutions we produce to help our customers reach their own ESG goals,” Mr. Clyburn continued. “Following the merger with DuPont’s Nutrition and Biosciences division, this report showcases our first year of results since launching our Do More Good Plan. We’re proud of the many ways we’re becoming a stronger, more resilient company, as we apply science and creativity for a better world.”
The 2021 ESG+ Report aligns with the Do More Good Plan’s four pillars: Sustainable Solutions, Climate and Planetary Health, Equity and Wellbeing, and Transparency & Accountability.
Examples of 2021 performance highlights and achievements include:
- Recognized for ESG leadership: named to the Dow Jones Sustainability Indices for the second consecutive year, received the EcoVadis platinum sustainability rating, and included in the Bloomberg Gender Equality Index
- Enabled and accelerated the wider adoption of sustainable solutions in the marketplace across divisions, and promoted circular economy growth through IFF products verified as Upcycled Certified™
- Continued commitment to climate action—being one of only 14 companies out of nearly 12,000 assessed—named by CDP as a triple A list company for corporate transparency on climate change, water stewardship and deforestation
- Strengthened commitment to diversity, equity and inclusion, honored by the Human Rights Campaign as a Best Place to Work for LGBTQ Equality for the third consecutive year, and named among the Best Places to Work for Disability Inclusion by Disability:IN for the second consecutive year
To read IFF’s 2021 ESG+ Report, click here or visit: https://www.iff.com/responsibilities/strategy-reporting/report-library .
Webcast
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ metrics and performance results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET. Mr. Clyburn will be joined by Michael DeVeau, Chief Investor Relations & Communications Officer; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Pete Sommers, Interim Chief Human Resources and Diversity, Equity & Inclusion Officer; and Kip Cleverley, Vice President, Global Sustainability & EHS. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com .
Investors and analysts are invited to participate by phone by calling 866-342-8591 from the United States and 203-518-9713 from other locations. The access code for the conference call is IFF0609. A live listen-only webcast will also be available at ir.iff.com . For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF)—an industry leader in food, beverage, scent, health and biosciences—science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005744/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Announces Key Executive Appointments for the Next Phase of Delivery15.6.2026 23:20:00 CEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release
A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release
- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
